XQ-2d sodium is an aptamer that targets TfR/CD71. XQ-2d binds to PL45 cells through recognizing CD71 protein.

Vortosiran, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.

Vortosiran sodium, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.

Volanesorsen scramble negative control is a negative control for volanesorsen) with the sequence: CAUGUTCUTCUGCATGUCAU. Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that can lower triglyceride levels and improve insulin resistance.

Vasoactive intestinal peptide is an agonist of VPAC1/VPAC2 receptor (G-protein-coupled receptors). Vasoactive intestinal peptide reduces corneal perforation rate, bacterial load, and excessive neutrophil infiltration in Pseudomonas aeruginosa-induced keratitis models. Vasoactive intestinal peptide enhances anti-inflammatory mediators like IL-10 and TGF-β, inhibites pro-inflammatory factors such as IL-1β and TNF-α, and upregulates lipid mediator-related enzymes (SOCS3, COX-2, ALOX12) to promote inflammation resolution. Vasoactive intestinal peptide is promising for research of ocular infectious diseases.

Superoxide dismutase PEG (EC 1.15.1.1) is a mimetic of superoxide dismutase (SOD) and powerful free radical scavenger acts by reducing superoxide anions.

Solbinsiran is a siRNA targeted to hepatic ANGPTL3.

Solbinsiran sodium is a siRNA targeted to hepatic ANGPTL3.

Senvesiran, a siRNA, is a ketohexokinase synthesis reducer.

Senvesiran sodium, a siRNA, is a ketohexokinase synthesis reducer.

Scrambled IONIS-MAPTRx (sodium) is a scrambled sequence of IONIS-MAPTRx sodium. Scrambled IONIS-MAPTRx (sodium) has the same amino acid composition as the active IONIS-MAPTRx sodium fragment, but the sequence is randomly scrambled. Scrambled IONIS-MAPTRx (sodium) is typically used as a negative control. Scrambled IONIS-MAPTRx (sodium) has potential for studying Alzheimer's disease.

Sapablursen, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen can be used in the research of blood diseases such as pol

Sapablursen sodium, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, which is the key regulator of iron homeostasis. Sapablursen sodium can be used in the research of blood diseas

Rimigorsen is an antisense oligonucleotide that induces skipping of exon 44 of the pre-mRNA encoding dystrophin in a Duchenne muscular dystrophy (DMD)

Rimigorsen sodium is an antisense oligonucleotide that induces skipping of exon 44 of the pre-mRNA encoding dystrophin in a Duchenne muscular dystrophy (DMD)

Renadirsen is an antisense oligonucleotide that induces robust Exon 45 skipping for Dystrophin in vivo.

Renadirsen sodium is an antisense oligonucleotide that induces robust Exon 45 skipping for Dystrophin in vivo.

Pixofisiran is a siRNA in STP705. It targets to TGF‐β1. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Pixofisiran sodium is a siRNA in STP705. It targets to TGF‐β1. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Pivicasiran, a siRNA, is a adiponutrin synthesis reducer.

Pivicasiran sodium, a siRNA, is a adiponutrin synthesis reducer.

Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

Opemalirsen sodium is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

Onvuzosiran, a siRNA, is a prekallikrein synthesis reducer.

Onvuzosiran sodium, a siRNA, is a prekallikrein synthesis reducer.

FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.

OZO-H is a GST inhibitor. OZO-H is an OZO derivative with potent anti-cancer effects. OZO-H releases JNK1 from GST-JNK1 complex. OZO-H induces JNK1 phosphorylation and activates c-Jun in cancer cells.

OZO-Cl is an OZO derivative. OZO-Cl has anti-cancer activity. OZO-Cl significantly decreases the intracellular glutathion S-transferase Pi (GST) activity. OZO-Cl exhibits cytotoxicity to cancer cell lines, with IC50s of 150 and 120 μmol/L in Panc-1 and K562 cells respectively.

Nucresiran is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nucresiran sodium is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.